Extrapyramidal symptoms


Also found in: Dictionary, Financial, Acronyms, Encyclopedia.

Extrapyramidal symptoms (EPS)

A group of side effects associated with antipsychotic medications. EPS include parkinsonism, akathisia, dystonia, and tardive dyskinesia.
Mentioned in: Schizophrenia
References in periodicals archive ?
Extrapyramidal symptoms (EPS) are most familiar side effect in patients treated chronically with first generation antipsychotics (FGAs).
In our study similar to the literature the main symptoms of the patients were psychomotor retardation, cerebellar ataxia, extrapyramidal symptoms, and seizures.
showed similar efficacy of the two antipsychotics in reducing psychosis in PD but higher tendency of risperidone to worsen extrapyramidal symptoms [50].
Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia.
Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.
The OAP recommended quetiapine as the first-line treatment for secondary mania in a web-based HIV Psychiatry Treatment Consensus Survey in 2010, [sup][18] presumably because of its benign effects with regard to extrapyramidal symptoms for diseases prominently affecting the basal ganglia, such as Parkinson's disease [sup][19] or HIV illness.
[15] The presence and degree of EPSs was assessed by making use of the Extrapyramidal Symptom Rating Scale (ESRS).
Commonly Observed Adverse Reactions: The most common adverse reactions (incidence > 5%, in either dose group, and at least twice the rate of placebo) in patients treated with LATUDA were akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, and anxiety.
According to Omeros the results showed that the selected dose of OMS824 achieved approximately 50% occupancy of PDE10 without triggering the extrapyramidal symptoms (loss of muscle control, e.g., muscle rigidity, tremors, or involuntary muscle movements) reported as side effects with other PDE10 inhibitors that achieved similar or significantly lower occupancy levels.
At least there was no deterioration in UPDRS which reflect the extrapyramidal symptoms and parkinsonism after the treatment with yokukansan.
All antipsychotics studied carried some risk of side effects, most I notably weight gain and extrapyramidal symptoms that may include involuntary body or facial movements, extreme restlessness, a shuffling gait, or other disruptions in normal movement.
It should be noted that Fanapt has virtually no risk of akathisia and extrapyramidal symptoms, unlike Saphris or Latuda, which have demonstrated dose-related effects.

Full browser ?